Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

TPMT genetic variations in populations of the Russian Federation.

Samochatova EV, Chupova NV, Rudneva A, Makarova O, Nasedkina TV, Fedorova OE, Glotov AS, Kozhekbaeva Zh, Maiorova OA, Roumyantsev AG, Krynetski EY, Krynetskaia NF, Evans WE, Ribeiro RC.

Pediatr Blood Cancer. 2009 Feb;52(2):203-8. doi: 10.1002/pbc.21837.

2.

A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress.

Brown VM, Krynetski EY, Krynetskaia NF, Grieger D, Mukatira ST, Murti KG, Slaughter CA, Park HW, Evans WE.

J Biol Chem. 2004 Feb 13;279(7):5984-92. Epub 2003 Nov 14.

3.

Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice.

Krynetskaia NF, Brenner TL, Krynetski EY, Du W, Panetta JC, Ching-Hon P, Evans WE.

Mol Pharmacol. 2003 Aug;64(2):456-65.

PMID:
12869651
5.

Structure and dynamics of thioguanine-modified duplex DNA.

Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW.

J Biol Chem. 2003 Jan 10;278(2):1005-11. Epub 2002 Oct 24.

7.

Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug.

Krynetskaia NF, Feng JY, Krynetski EY, Garcia JV, Panetta JC, Anderson KS, Evans WE.

FASEB J. 2001 Sep;15(11):1902-8.

PMID:
11532970
8.

Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.

Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV.

Cancer Res. 2001 Aug 1;61(15):5810-6.

9.

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV.

J Clin Oncol. 2001 Apr 15;19(8):2293-301.

PMID:
11304783
10.

A novel protein complex distinct from mismatch repair binds thioguanylated DNA.

Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE.

Mol Pharmacol. 2001 Feb;59(2):367-74.

PMID:
11160874
11.

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.

Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV.

FASEB J. 2000 Nov;14(14):2339-44.

PMID:
11053256
12.

Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance.

Krynetski EY, Evans WE.

Pharmacology. 2000 Sep;61(3):136-46. Review.

PMID:
10971199
13.

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.

McLeod HL, Krynetski EY, Relling MV, Evans WE.

Leukemia. 2000 Apr;14(4):567-72. Review.

14.
15.

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.

J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8.

PMID:
10580024
16.

Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA.

Krynetskaia NF, Krynetski EY, Evans WE.

Mol Pharmacol. 1999 Oct;56(4):841-8.

PMID:
10496969
17.

Synthesis of modified thiopurine nucleosides for structural characterization of human thiopurine S-methyltransferase.

Korshunova GA, Krynetski EY, Mtchedlidze MT, Agapkin DV, Evans WE, Krynetskaia NF.

Nucleosides Nucleotides. 1999 Jun-Jul;18(6-7):1747-8.

PMID:
10474258
18.
19.

Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE.

Blood. 1999 Mar 1;93(5):1643-50.

PMID:
10029593
20.

Polymorphism of the thiopurine S-methyltransferase gene in African-Americans.

Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE.

Hum Mol Genet. 1999 Feb;8(2):371-6.

PMID:
9931346
21.

Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter.

Fessing MY, Krynetski EY, Zambetti GP, Evans WE.

Eur J Biochem. 1998 Sep 15;256(3):510-7.

22.
23.

Pharmacogenetics of cancer therapy: getting personal.

Krynetski EY, Evans WE.

Am J Hum Genet. 1998 Jul;63(1):11-6. Review. No abstract available.

24.

Structural and functional analysis of the human TPMT gene promoter.

Fessing MY, Krynetski EY, Schuetz JD, Evans WE.

Adv Exp Med Biol. 1998;431:315-8. No abstract available.

PMID:
9598082
25.
26.

Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library.

Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE.

Pharm Res. 1997 Dec;14(12):1672-8.

PMID:
9453052
27.
28.

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.

Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE.

Ann Intern Med. 1997 Apr 15;126(8):608-14.

PMID:
9103127
29.

Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE.

Pharmacogenetics. 1996 Aug;6(4):279-90. Review.

PMID:
8873214
30.

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE.

Am J Hum Genet. 1996 Apr;58(4):694-702.

31.

Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults.

McLeod HL, Krynetski EY, Wilimas JA, Evans WE.

Pharmacogenetics. 1995 Oct;5(5):281-6.

PMID:
8563768
32.

Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.

Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE.

Mol Pharmacol. 1995 Jun;47(6):1141-7.

PMID:
7603453
33.

High yield expression of functionally active human liver CYP2D6 in yeast cells.

Krynetski EY, Drutsa VL, Kovaleva IE, Luzikov VN.

Pharmacogenetics. 1995 Apr;5(2):103-9.

PMID:
7663527
34.

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE.

Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53.

Supplemental Content

Loading ...
Support Center